Ipsen presents new neurological data at TOXINS 2026
Ipsen presented 14 abstracts at TOXINS 2026, including an interim EPITOME analysis reporting that 45.7% of stroke survivors with paresis developed post‑stroke spasticity within one year; the company also cited evidence that under 1% of stroke survivors receive BoNT‑A treatment for spasticity in routine practice.
